CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer

被引：0
|
作者：
Forstmeyer, D. [1 ]
机构：
[1] Univ Klinikum Leipzig, Univ Krebszentrum Leipzig UCCL, Liebigstr 20, D-04103 Leipzig, Germany
来源：
ONKOLOGE | 2016年 / 22卷 / 07期
关键词：
PALBOCICLIB;
D O I：
10.1007/s00761-016-0055-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：507 / 508
页数：2
相关论文
共 50 条
  • [1] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [2] Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
    Jeong, J. H.
    Jeong, H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2021, 32 : S72 - S73
  • [3] CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
    Fedele, Palma
    Cinieri, Saverio
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) : 1237 - 1239
  • [4] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
    Pla, Helena
    Felip, Eudald
    Obadia, Veronica
    Pernas, Sonia
    Vinas, Gemma
    Margeli, Mireia
    Fort-Culillas, Roser
    Del Barco, Sonia
    Sabate, Nuria
    Fort, Eduard
    Lezcano, Clara
    Cirauqui, Beatriz
    Quiroga, Vanesa
    Stradella, Agostina
    Gil, Miguel Gil
    Esteve, Anna
    Recalde, Sabela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
  • [5] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Shah, Ami N.
    Lim, Bora
    Mita, Monica M.
    Mauer, Elizabeth
    Layng, Kayla V.
    Chao, Calvin
    Brufsky, Adam M.
    CANCER RESEARCH, 2023, 83 (05)
  • [6] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Grinshpun, Albert
    Tolaney, Sara M. M.
    Burstein, Harold J. J.
    Jeselsohn, Rinath
    Mayer, Erica L. L.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [7] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    npj Breast Cancer, 9
  • [8] Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
    Abdel-Razeq, Hikmat
    Sharaf, Baha'
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 727 - 735
  • [9] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [10] Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience
    Kurbacher, Christian M.
    Fischer, Lotta Ada
    Heinrich, Georg
    Herz, Susanne
    Schott, Alexander
    Kurbacher, A. Tabea
    Kurbacher, Jutta Anna
    Rudlowski, Christian
    Warm, Mathias R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 19 - 19
12345